Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

Keyphrases

• Metastatic Melanoma 100%
• MEK Inhibitor (MEKi) 100%
• Inhibitor Response 100%
• RAF1 Fusion 100%
• Mitogen-activated Protein Kinase 33%
• Catenin 33%
• Therapeutic Target 33%
• Clinically Significant 33%
• Cancer Types 33%
• Cell Death 33%
• Structural Arrangement 33%
• Targeted Therapy 33%
• Pathogenic Variants 33%
• Molecular Characterization 33%
• Improved Patient Outcomes 33%
• Tumor Progression 33%
• Melanoma 33%
• ERK Activation 33%
• Treatment-resistant 33%
• CTNNB1 33%
• Serine-threonine Kinase 33%
• Therapy Management 33%
• Inhibitor Therapy 33%
• Combination Immunotherapy 33%
• RAF1 33%
• Ki-67 Index 33%
• Drug-resistant Cancer 33%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 33%
• ETV5 33%
• Anti-CTLA-4 33%
• Actionable Variants 33%
• Dramatic Response 33%
• Anti-cytotoxic 33%
• Fusion Variants 33%
• Potential Action 33%

Medicine and Dentistry

• MEK Inhibitor 100%
• Melanoma Skin Cancer 100%
• Cancer 50%
• Cancer Types 50%
• Cell Death 50%
• Targeted Therapy 50%
• Immunotherapy 50%
• Tumor Progression 50%
• Cell Signaling Pathway 50%
• Catenin 50%
• Action Potential 50%
• Metastatic Melanoma 50%
• Protein Serine Threonine Kinase 50%
• MAPK Signaling 50%
• B Raf Kinase 50%
• Cyclin Dependent Kinase Inhibitor 2A 50%
• Melanoma 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Mitogen Activated Protein Kinase Kinase Inhibitor 100%
• Cutaneous Melanoma 100%
• Tumor Growth 50%
• Malignant Neoplasm 50%
• Melanoma 50%
• Immunotherapy 50%
• Catenin 50%
• Protein Serine Threonine Kinase 50%
• Metastatic Melanoma 50%
• Cyclin Dependent Kinase Inhibitor 2A 50%
• B Raf Kinase 50%
• Cytotoxic T Lymphocyte Antigen 4 50%